Core Viewpoint - Novo Nordisk's innovative drug amycretin shows significant weight loss results in clinical trials, indicating a promising new treatment option for obesity and type 2 diabetes patients [6][7][9]. Group 1: Clinical Trial Results - The clinical trial results for amycretin were presented at the 85th American Diabetes Association (ADA) Scientific Sessions, highlighting its effectiveness in weight reduction among overweight or obese individuals [6][7]. - In a 36-week treatment period, the 60 mg dose group experienced an average weight loss of 24.3%, compared to a 1.1% increase in the placebo group [7]. - The 20 mg dose group achieved a 22.0% weight loss, while the 5 mg and 1.25 mg groups showed weight reductions of 16.2% and 9.7%, respectively, with all groups outperforming the placebo [7]. Group 2: Safety and Tolerability - Amycretin demonstrated excellent tolerability, with adverse reactions primarily related to the gastrointestinal system, consistent with other GLP-1 and incretin receptor agonists [7][8]. - Most adverse events were mild to moderate and resolved by the end of the trial, indicating a favorable safety profile [7]. Group 3: Oral Administration Results - The oral formulation of amycretin also showed promising results, with participants experiencing weight reductions of 10.4% and 13.1% after 12 weeks for the once-daily and twice-daily dosing regimens, respectively [8]. - The oral administration maintained a good safety profile, with adverse events aligning with expected outcomes for GLP-1 and incretin receptor mechanisms [8]. Group 4: Future Development - Novo Nordisk is accelerating the development of both the injectable and oral forms of amycretin, with ongoing phase 3 clinical trials to evaluate its potential as a next-generation weight management solution [9].
《柳叶刀》重磅发布:诺和诺德减重新星创纪录!36周显效,体重骤减近四分之一